Head to head
UiPath vs Microsoft
Side-by-side on the measures that matter, with a plain-English read. Full detail: PATH · MSFT
PATH
UiPath
13.07-0.23%
1-year price shape — -12% over the period
Quant Rating D · 27/100
vs
MSFT
Microsoft
529.76+0.09%
1-year price shape — +2% over the period
Quant Rating C · 40/100
1-year performance, rebased to 100
Microsoft edges it on the scoreable measures. Microsoft has the highest Quant Rating (40); Microsoft has done best over the past year (+2%); Microsoft pays the highest dividend yield.
| PATH | MSFT | |
|---|---|---|
| Snapshot | ||
| Sector | Software - Infrastructure | Software - Infrastructure |
| Last price | 13.07 | 529.76 |
| Change today | -0.23% | +0.09% |
| 1-year return | -11.8% | +1.9% |
| Market cap | $6.81B | $3.93T |
| 52-week range | 9.20 – 19.84 | 348.54 – 549.20 |
| Valuation | ||
| P/E (TTM) | 19.51 | 29.51 |
| P/E percentile, own 5-yr range | 82nd | 30th |
| P/B | 3.50 | 8.89 |
| Dividend yield | 0.00% | 0.67% |
| Profitability & growth | ||
| EPS (TTM) | 0.52 | 17.95 |
| Net profit (TTM) | $271.00M | $133.29B |
| Revenue (TTM) | $1.72B | $331.84B |
| Revenue growth (YoY) | +13.4% | +17.7% |
| Gross margin | 82.6% | 67.9% |
| Operating margin | 8.9% | 46.8% |
| Net margin | 21.0% | 40.3% |
| Free cash flow (TTM) | $362.96M | $66.99B |
| Ownership & sentiment | ||
| Institutional ownership | 76.3% | 75.3% |
| Insider activity (12mo) | 20 buy / 28 sell | 31 buy / 16 sell |
| Short interest (% of float) | 20.0% | 0.9% |
| Analyst consensus | 14% buy / 71% hold / 14% sell (14) | 100% buy (32) |
| Analyst price target | $16 (+21%) | $582 (+10%) |
| StockVane view | ||
| StockVane Quant Rating | D (27) | C (40) |
| Company | ||
| Employees | 3,981 | 223,000 |
| Founded | 2005 | 1975 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.